Backed by $52 million in Series A financing led by 8VC and named after a feat of engineering in ancient Rome, Appia Bio jumped into the cell therapy fray this morning with a promising scalable technology platform.
Other articles
January 14, 2026
Five Berkeley Spinouts Reflect Our Simple Thesis: Back Insatiably Curious Scientists Tackling Massive Problems
At Freeflow Ventures, our investment thesis is straightforward: we back…



